BRAF-targeted therapy and immune responses to melanoma

SF Ngiow; DA Knight; A Ribas; GA McArthur; MJ Smyth

Journal article

BRAF-targeted therapy and immune responses to melanoma

SF Ngiow, DA Knight, A Ribas, GA McArthur, MJ Smyth

Oncoimmunology | LANDES BIOSCIENCE | Published : 2013

DOI: 10.4161/onci.24462

Download PDF

Abstract

Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the treatment of advanced malignant melanoma. We have recently elucidated a role for host C-C chemokine receptor Type 2 (CCR2) in the antineoplastic effects of Type I BRAF inhibitors in mice, supporting the therapeutic potential of combining BRAF inhibitors with immunotherapy. © 2013 Landes Bioscience.

University of Melbourne Researchers

Grant McArthur Author

Related Projects (3)

IMMUNE REGULATION EFFECTOR FUNCTION AND THERAPY

We seek to understand how white blood cells detect and destroy disease, and how molecules of the immune system punch holes in diseased cells..

IMMUNE REGULATION EFFECTOR FUNCTION AND THERAPY

We seek to understand how white blood cells detect and destroy disease, and how molecules of the immune system punch holes in diseased cells..

Understanding Inhibition of BRAF in Melanoma

Recent clinical studies have shown that the most common mutation found in melanoma in the gene BRAF can be successfully targeted for treatme..

Grants

Awarded by Cancer Research Institute

Funding Acknowledgements

GAM declares financial research support from Pfizer, Novartis and Millenium. This work was supported by the National Health and Medical Research Council of Australia (NH&MRC) Program Grant (1013667), Project Grant (1002655) and the Victorian Cancer Agency. MJS received support from a NH&MRC Australia Fellowship. SN was supported by a Cancer Research Institute PhD scholarship. GM received support from a NH&MRC Practitioner Fellowship.